Find a study
Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.
3 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Kidney disease
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
Testing whether a weekly diabetes medicine is safe for people on dialysis
📍 Unity Health Toronto · Toronto, Ontario · Get directions →
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
- Fatty liver disease (NASH/MASH)💵 May compensate
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Testing whether survodutide helps adults with MASH and moderate to advanced liver scarring
📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →
This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function.
- Fatty liver disease (NASH/MASH)💵 May compensate
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Testing whether survodutide helps adults with NASH/MASH cirrhosis
📍 The Institute for Liver Health II DBA Arizona Clinical Trials · Peoria, AZ · +39 more US sites · Get directions →
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study.